A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
for Triple Negative Breast Cancer
Sites in Norfolk +8 more locations
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT06926920·Phase 1, Phase 2·Recruiting·Listed Apr 2025